Patients with metastatic pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as long when switched to a once-daily oral drug called daraxonrasib, according to results from a 500-patient Phase 3 trial. Median overall survival reached 13.2 months with the pill compared with 6.7 months for those who continued on physician-chosen chemotherapy, producing a hazard ratio of 0.40. The findings, from the RASolute 302 trial, represent the first time a RAS-targeting oral therapy has doubled survival in a randomized study of previously treated pancreatic cancer.
Why a RAS-blocking pill changes the calculus for pancreatic cancer treatment
Pancreatic ductal adenocarcinoma kills most patients within a year of diagnosis, and second-line chemotherapy regimens have offered only modest extensions of life, often at the cost of severe toxicity that keeps patients tethered to infusion centers. Daraxonrasib, also designated RMC-6236, works through a different mechanism. It is an oral inhibitor that locks onto the active, GTP-bound form of RAS proteins by forming a tri-complex with cyclophilin A, a naturally occurring cellular protein. That tri-complex design allows the drug to block multiple RAS variants rather than a single mutation, which matters because roughly 90 percent of pancreatic tumors harbor some form of KRAS alteration.
The practical difference for patients is straightforward: a pill taken at home versus hours in an infusion chair. Investigators at UCLA reported higher rates of tumor shrinkage and steadier pain control with daraxonrasib than with standard chemotherapy, suggesting the survival advantage was not purchased at the price of worse daily life. Whether the drug’s broad RAS-blocking activity produces even larger benefits in tumors that carry additional downstream alterations in the RAF or MEK signaling pathways is an open question. Because daraxonrasib hits the upstream RAS switch rather than a single downstream node, patients with co-occurring pathway mutations could theoretically see a compounding effect, though the trial data released so far have not broken out that subgroup.
RASolute 302 trial results in the New England Journal of Medicine
The RASolute 302 trial, also listed on ClinicalTrials.gov, randomized approximately 500 participants across sites in multiple countries. Patients had metastatic pancreatic ductal adenocarcinoma that had progressed on at least one prior line of therapy. The primary endpoint was overall survival, and the trial met it decisively: the hazard ratio of 0.40 carried a P-value below 0.001 in both the intent-to-treat population and the RAS G12 subgroup. In the RAS G12 population specifically, median overall survival was 13.2 months with daraxonrasib versus 6.6 months with chemotherapy.
Those numbers are striking in a disease where second-line options have historically added only weeks. A hazard ratio of 0.40 means the risk of death at any given point was 60 percent lower for patients on the oral drug. The consistency of the benefit across the full trial population and the RAS G12 subset suggests the drug’s activity is not limited to a narrow molecular slice of pancreatic cancer. UCLA investigators who participated in the study noted that patients on daraxonrasib also experienced higher objective response rates and more stable pain trajectories than those receiving chemotherapy, though the full adverse-event tables and grade 3–4 toxicity breakdowns have not yet been published in detail beyond the journal abstract.
Beyond overall survival, the trial reported improvements in progression-free survival and tumor control rates that tracked with the survival advantage. More patients receiving daraxonrasib saw their tumors shrink or remain stable for several months, which likely contributed to the observed reductions in pain flares and the decreased need for opioid dose escalations described by investigators. These clinical benefits appeared across age groups and performance-status categories, reinforcing the impression that the drug could be suitable for a broad slice of the metastatic pancreatic cancer population, provided their tumors carry RAS alterations.
How daraxonrasib fits into the broader treatment landscape
Until now, second-line therapy for metastatic pancreatic cancer has typically meant regimens such as nanoliposomal irinotecan plus fluorouracil or oxaliplatin-based combinations, each associated with substantial risks of neutropenia, neuropathy, and gastrointestinal side effects. These treatments require frequent clinic visits, blood count monitoring, and infusion chair time, all of which can erode quality of life for patients whose prognosis is already limited. An oral RAS inhibitor that can be taken at home, with survival benefits on the order of several additional months, represents a meaningful shift in the risk–benefit calculation.
Daraxonrasib’s mechanism of targeting the active, GTP-bound state of RAS may also have implications beyond pancreatic cancer. Because many solid tumors depend on hyperactive RAS signaling, oncologists are watching closely to see whether the drug’s tri-complex approach can be generalized. For pancreatic cancer specifically, however, the immediate question is how best to integrate the pill into existing treatment sequences. If future studies show similar or greater benefits in earlier lines of therapy, daraxonrasib could move up to first-line use, potentially in combination with standard chemotherapy or other targeted agents.
In practice, implementation will hinge on reliable molecular testing. The RASolute 302 population was enriched for tumors with documented RAS mutations, particularly in the G12 codon. Wider adoption of comprehensive genomic profiling at diagnosis would ensure that eligible patients are identified early enough to benefit from RAS-directed therapy once standard first-line regimens stop working. Community oncology practices, which see a large share of pancreatic cancer cases, may need support to expand access to timely sequencing and to interpret increasingly complex molecular reports.
Gaps in the data and what patients should watch for next
Several pieces of the clinical picture are still missing. The published results do not yet include complete safety tables showing how often patients experienced serious side effects, what dose reductions or interruptions were needed, or how adherence held up over months of daily pill-taking. Patient-reported quality-of-life scores have been referenced in institutional summaries but do not appear as formal endpoints in the trial registry record. Long-term survival curves beyond the median follow-up period are also absent, leaving open the question of whether a meaningful fraction of patients achieve durable responses lasting well beyond 13 months.
The hypothesis that co-occurring RAF or MEK pathway alterations might predict an even larger benefit is testable through retrospective biomarker analysis of banked tumor tissue from the trial. If that analysis confirms a gradient of benefit tied to pathway complexity, it could reshape how oncologists select patients for the drug versus combination strategies. It might also inform rational pairings of daraxonrasib with downstream inhibitors to forestall resistance mechanisms that reactivate the pathway. For now, the trial data support daraxonrasib as a clear advance over second-line chemotherapy for previously treated metastatic pancreatic cancer carrying RAS mutations.
Regulatory review will be the next major inflection point. The strength of the survival data and the randomized design position daraxonrasib as a candidate for priority consideration, but regulators will scrutinize the emerging safety profile, the maturity of follow-up, and the generalizability of the trial population. Health systems and payers, in turn, will weigh the cost of a targeted oral therapy against the expense and toxicity burden of multi-agent chemotherapy. Real-world studies, if launched promptly after any approval, could help clarify how the drug performs outside academic centers and whether adherence challenges or drug–drug interactions blunt its benefits.
Patients currently on or approaching second-line treatment for metastatic pancreatic cancer should ask their oncologists whether the RASolute 302 data apply to their tumor’s molecular profile. The drug is not yet approved by the U.S. Food and Drug Administration, so access in the near term will likely be limited to clinical trials or expanded-access programs, where available. Discussing genomic testing, potential eligibility for RAS-targeted studies, and the trade-offs between continuing infusion-based chemotherapy versus switching to an oral agent can help patients align their treatment choices with their goals and tolerance for side effects. As more detailed safety and quality-of-life results emerge, those conversations should become easier, but for now daraxonrasib stands out as a rare example of a late-line therapy that meaningfully extends life in one of oncology’s most lethal cancers.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
